$CLMT

Two Seas Capital (CLMT) discloses 7.5% Calumet stake via Two Seas Global Fund

Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi filed Amendment No. 3 to a Schedule 13G reporting beneficial ownership of 6,619,708 shares of Calumet, Inc. common stock, or 7.5%, as of June 30, 2026. The stake is held by Two Seas Global (Master) Fund LP, with sole voting and dispositive power reported.

Original reporting
Published Aug 14, 2026, 8:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

A disclosed 7.5% stake can raise attention around governance and takeover optionality, but the filing type (13G) and lack of stated intent reduce the probability of immediate fundamental catalysts.

02

Market read

Traders may use the stake size and sole voting/dispositive power as a signal to watch for future governance or strategic actions, but no such actions are disclosed here.

03

What to watch

The article does not state whether the position is newly initiated versus previously held, nor does it provide any activist or governance agenda, limiting immediate tradability.

Relevance 4/10Novelty 5/10Timing: after-hours filing disclosure dated for June 30, 2026 stake

Background

The article summarizes an SEC Schedule 13G Amendment No. 3 reporting beneficial ownership of Calumet common stock by Two Seas Capital and related persons.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Two Seas Capital reports a 7.5% beneficial ownership stake in Calumet, Inc. via an Amendment No. 3 to its Schedule 13G as of June 30, 2026.

Expected impact

Likely limited near-term price impact; any move would depend on follow-on disclosures (13D, activism, board/financing plans) not present here.

Evidence & confidence

This is a Schedule 13G/A beneficial ownership disclosure (passive/IA-style reporting) with no stated intent, deal, or operational change. The only concrete datapoint is the 7.5% stake and sole voting/dispositive power.

Market effects

Minimal sector read-through; this is company-specific ownership reporting without operational or regulatory developments.

None indicated.

None indicated.

Counterpoint

A 7.5% stake could be a precursor to a more assertive 13D campaign, so traders may want to monitor for subsequent intent disclosures rather than treat this as purely passive.

Key entities

  • Calumet, Inc.

    Subject of the ownership disclosure; beneficially owned shares reported as 7.5% as of June 30, 2026.

  • Two Seas Capital LP

    Investment adviser reporting beneficial ownership through its fund vehicle.

  • Two Seas Global (Master) Fund LP

    Entity holding the reported Calumet shares.

  • Sina Toussi

    Chief investment officer and managing member named as a reporting person.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.